Jennison Associates’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$4.65B Sell
5,060,878
-72,798
-1% -$73.8M 3.2% 7
2025
Q4
$5.52B Buy
5,133,676
+937,204
+22% +$896M 3.31% 7
2025
Q3
$3.2B Sell
4,196,472
-1,251,164
-23% -$931M 1.86% 12
2025
Q2
$4.25B Buy
5,447,636
+226,620
+4% +$176M 2.52% 8
2025
Q1
$4.31B Buy
5,221,016
+424,693
+9% +$353M 3.02% 8
2024
Q4
$3.7B Sell
4,796,323
-2,151,072
-31% -$1.78B 2.25% 9
2024
Q3
$6.15B Sell
6,947,395
-285,593
-4% -$257M 3.82% 7
2024
Q2
$6.55B Sell
7,232,988
-233,514
-3% -$187M 4.2% 6
2024
Q1
$5.81B Sell
7,466,502
-131,110
-2% -$93.3M 3.88% 5
2023
Q4
$4.43B Sell
7,597,612
-810,001
-10% -$473M 3.3% 5
2023
Q3
$4.52B Sell
8,407,613
-173,825
-2% -$89.6M 3.83% 6
2023
Q2
$4.02B Buy
8,581,438
+7,274
+0.1% +$3.05M 3.3% 6
2023
Q1
$2.94B Sell
8,574,164
-1,854,917
-18% -$626M 2.7% 6
2022
Q4
$3.82B Buy
10,429,081
+364,339
+4% +$129M 3.87% 3
2022
Q3
$3.25B Sell
10,064,742
-293,324
-3% -$92.9M 3.24% 5
2022
Q2
$3.36B Buy
10,358,066
+2,456,760
+31% +$737M 3.35% 5
2022
Q1
$2.26B Sell
7,901,306
-1,254,308
-14% -$323M 1.67% 14
2021
Q4
$2.53B Sell
9,155,614
-708,902
-7% -$180M 1.6% 15
2021
Q3
$2.28B Buy
9,864,516
+953,521
+11% +$235M 1.47% 20
2021
Q2
$2.05B Buy
8,910,995
+3,470,858
+64% +$697M 1.36% 24
2021
Q1
$1.02B Buy
5,440,137
+3,561,294
+190% +$697M 0.74% 39
2020
Q4
$317M Sell
1,878,843
-2,701,830
-59% -$403M 0.23% 57
2020
Q3
$678M Sell
4,580,673
-3,482,699
-43% -$539M 0.55% 47
2020
Q2
$1.32B Sell
8,063,372
-2,128,680
-21% -$327M 1.2% 23
2020
Q1
$1.41B Buy
10,192,052
+5,679,574
+126% +$780M 1.72% 18
2019
Q4
$593M Buy
4,512,478
+3,157,292
+233% +$366M 0.6% 44
2019
Q3
$152M Sell
1,355,186
-218,457
-14% -$24.3M 0.16% 77
2019
Q2
$174M Sell
1,573,643
-2,077,373
-57% -$245M 0.17% 72
2019
Q1
$474M Buy
3,651,016
+225,592
+7% +$27.4M 0.47% 48
2018
Q4
$396M Buy
3,425,424
+1,280,878
+60% +$143M 0.44% 49
2018
Q3
$230M Buy
2,144,546
+242,577
+13% +$24.3M 0.21% 59
2018
Q2
$162M Buy
1,901,969
+8,272
+0.4% +$679K 0.16% 82
2018
Q1
$147M Sell
1,893,697
-383,990
-17% -$30.9M 0.15% 92
2017
Q4
$192M Buy
2,277,687
+270,921
+14% +$23.1M 0.19% 70
2017
Q3
$172M Buy
2,006,766
+59,705
+3% +$4.9M 0.18% 77
2017
Q2
$160M Buy
1,947,061
+237,342
+14% +$19.4M 0.17% 86
2017
Q1
$144M Sell
1,709,719
-25,691
-1% -$2.06M 0.15% 98
2016
Q4
$128M Buy
1,735,410
+441,381
+34% +$32.9M 0.14% 117
2016
Q3
$104M Sell
1,294,029
-12,057
-0.9% -$965K 0.11% 154
2016
Q2
$103M Buy
1,306,086
+756,569
+138% +$57M 0.11% 158
2016
Q1
$39.6M Sell
549,517
-610
-0.1% -$46.2K 0.04% 321
2015
Q4
$46.4M Sell
550,127
-517,393
-48% -$42.9M 0.05% 296
2015
Q3
$89.3M Buy
1,067,520
+14,615
+1% +$1.23M 0.09% 198
2015
Q2
$87.9M Buy
1,052,905
+8,569
+0.8% +$653K 0.08% 226
2015
Q1
$75.9M Sell
1,044,336
-7,154
-0.7% -$509K 0.07% 256
2014
Q4
$72.5M Buy
+1,051,490
New +$71M 0.07% 261
2014
Q3
Sell
-61,216
Closed -$3.81M 739
2014
Q2
$3.81M Buy
61,216
+11,206
+22% +$669K ﹤0.01% 523
2014
Q1
$2.94M Sell
50,010
-18,373
-27% -$1.03M ﹤0.01% 557
2013
Q4
$3.49M Buy
68,383
+6,147
+10% +$308K ﹤0.01% 521
2013
Q3
$3.13M Buy
+62,236
New +$3.26M ﹤0.01% 536

Other funds holding LLY

Jennison Associates's LLY Position: Q1 2026 in Review

Jennison Associates reduced its Eli Lilly (LLY) stake by 1.4% in Q1 2026, selling an estimated $73.8M and leaving 5,060,878 shares worth $4.65B. The position accounts for 3.2% of the portfolio, ranked #7.

Jennison Associates first reported a position in LLY in Q3 2013 and has held it in 50 quarters since. The position peaked at $6.55B in Q2 2024. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Jennison Associates held 5,060,878 shares of Eli Lilly worth $4.65B as of Q1 2026.
  • Jennison Associates sold 72,798 Eli Lilly shares in Q1 2026, an estimated $73.8M.
  • Eli Lilly made up 3.2% of Jennison Associates's portfolio in Q1 2026, its #7 holding.
  • Jennison Associates first reported a position in Eli Lilly in Q3 2013 and has held it in 50 quarters since.
  • Jennison Associates's Eli Lilly position peaked at $6.55B in Q2 2024.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Jennison Associates's 13F filing for Q1 2026, filed 6 May 2026.